
Air Canada and Transat stated they agreed to scuttle the proposed acquisition of Transat by Air Canada after European antitrust authorities indicated the deal wouldn’t receive their blessing, reported The Wall Street Journal.
The deal, disclosed in June 2019, was conditional on approval from various regulators. Canada’s Liberal government approved the transaction in February —even though Canada’s antitrust watchdog, the Competition Bureau, had serious reservations about the deal and its impact on competition.
Following recent discussions with the European Commission, Air Canada stated Friday, April 2, it was evident the commission “will not approve the acquisition based on the currently offered remedy package” to alleviate any competition concerns.
Air Canada also stated, “After careful consideration, Air Canada has concluded that providing additional, onerous remedies, which may still not secure commission approval, would significantly compromise Air Canada’s ability to compete internationally, negatively impacting customers, other stakeholders and future prospects as it recovers and rebuilds from the impact of the Covid-19 pandemic.”
Air Canada stated it would pay Transat a termination fee of CA$12.5 million (US$10 million).
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas